HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

EHT 1864

inhibits Rac1 signaling; structure in first source

Also Known As:

EHT-1864; EHT1864

Networked: 9 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrans: 130
    - Pyrones: 35
      - EHT 1864: 9
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - EHT 1864: 9

Experts

1.	Désiré, Laurent: 2 articles (03/2017 - 04/2011)
2.	Almeida, Michael F: 1 article (01/2019)
3.	Bahnson, Edward M: 1 article (01/2019)
4.	Bahr, Ben A: 1 article (01/2019)
5.	Grant, Ruriko: 1 article (01/2019)
6.	Hagaman, John R: 1 article (01/2019)
7.	Jennette, J Charles: 1 article (01/2019)
8.	Kakoki, Masao: 1 article (01/2019)
9.	Kayashima, Yukako: 1 article (01/2019)
10.	Lee, Esther Y: 1 article (01/2019)

Related Diseases

1.	Neoplasms (Cancer) 03/28/2017 - "EHT1864 suppressed growth of HER2+ tumors, and enhanced response to anti-estrogen treatment in ER+ tumors. " 06/01/2012 - "EHT 1864, a small molecule inhibitor of Rac GTPases, prevents spread of breast cancers in this setting, and also reduces proliferation at the invading edge. " 03/28/2017 - "Comparison of the growth-inhibitory profile of EHT1864 to 137 other anti-cancer drugs across 656 cancer cell lines revealed significant correlation with the p70S6K inhibitor PF-4708671. " 01/01/2018 - "Brefeldin A and EHT-1864, agents that significantly inhibit VEGF secretion, decreased stem cell self-renewal, inhibited tumor growth, and increased the survival of mice allografted with S100β-v-erbB/p53-/- glioma stem-like cells. "
2.	Breast Neoplasms (Breast Cancer) 03/28/2017 - "We tested response to the Rac inhibitor EHT1864 in a panel of breast cancer cell lines. " 04/01/2011 - "Since ERα plays a critical role in the pathogenesis of breast cancer and the Rac inhibitor EHT 1864 down-regulates ERα expression and breast cancer cell proliferation, further investigation of the therapeutic potential of Rac1 targeting in the treatment of breast cancer is warranted." 04/01/2011 - "Therefore, ERα down-regulation by EHT 1864 is the likely mechanism of EHT 1864-mediated inhibition of ERα activity and estrogen-stimulated breast cancer cell proliferation. " 04/01/2011 - "Furthermore, EHT 1864 inhibited estrogen-induced cell proliferation in breast cancer cells and decreased tamoxifen-resistant breast cancer cell growth. "
3.	Acute Kidney Injury (Acute Renal Failure) 01/01/2022 - "EHT 1864 and salubrinal have potential as drug candidates in patients with septic acute kidney injury."
4.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 08/01/2013 - "Monocytic MLL-AF9 expressing cells (MM6, THP-1) were hypersensitive to both small-molecule inhibitors targeting Rac1 (EHT 1864, NSC 23766) (IC50EHT ~12.5 μM) and lipid lowering drugs (lovastatin, atorvastatin) (IC50Lova ~7.5 μM) as compared to acute myelocytic leukemia (NOMO-1, HL60) and T cell leukemia (Jurkat) cells (IC50EHT >30 μM; IC50Lova >25 μM). "
5.	T-Cell Leukemia (Leukemia, T Cell) 08/01/2013 - "Monocytic MLL-AF9 expressing cells (MM6, THP-1) were hypersensitive to both small-molecule inhibitors targeting Rac1 (EHT 1864, NSC 23766) (IC50EHT ~12.5 μM) and lipid lowering drugs (lovastatin, atorvastatin) (IC50Lova ~7.5 μM) as compared to acute myelocytic leukemia (NOMO-1, HL60) and T cell leukemia (Jurkat) cells (IC50EHT >30 μM; IC50Lova >25 μM). "

Related Drugs and Biologics

1.	Estrogens (Estrogen)
2.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
3.	70-kDa Ribosomal Protein S6 Kinases (Ribosomal Protein S6 Kinases, 70 kDa)
4.	GTP Phosphohydrolases (GTPases)
5.	Brefeldin A
6.	Dextran Sulfate
7.	Tamoxifen
8.	Lovastatin (Mevacor)
9.	Lipids
10.	Doxorubicin (Adriamycin)

Related Therapies and Procedures

1.	Oral Administration